Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice

[1]  D. Berd.  M-Vax: an autologous, hapten-modified vaccine for human cancer , 2004, Expert review of vaccines.

[2]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[3]  P. Burkett,et al.  Regulation of lymphoid homeostasis by interleukin-15. , 2002, Cytokine & growth factor reviews.

[4]  R. Kennedy,et al.  Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  I. L. Le Poole,et al.  Emerging strategies in tumor vaccines. , 2002, Current opinion in oncology.

[6]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[7]  J. Norton,et al.  Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. , 2002, Cancer research.

[8]  P. Musiani,et al.  IFN‐γ‐independent synergistic effects of IL‐12 and IL‐15 induce anti‐tumor immune responses in syngeneic mice , 2002, European journal of immunology.

[9]  M. Caligiuri,et al.  Interleukin-2 and interleukin-15: immunotherapy for cancer. , 2002, Cytokine & growth factor reviews.

[10]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[11]  S. Koyasu,et al.  Critical role of IL-15–IL-15R for antigen-presenting cell functions in the innate immune response , 2001, Nature Immunology.

[12]  P. Hertzog,et al.  Differential Production of IL-12, IFN-α, and IFN-γ by Mouse Dendritic Cell Subsets1 , 2001, The Journal of Immunology.

[13]  C. H. Park,et al.  Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. , 2001, Human gene therapy.

[14]  Xinjian Zhang,et al.  Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site , 2001, Cancer Gene Therapy.

[15]  Lieping Chen,et al.  IL-12 gene therapy for cancer: in synergy with other immunotherapies. , 2001, Trends in immunology.

[16]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[17]  M. Atkins,et al.  Agranulocytosis and Hemolytic Anemia in Patients With Renal Cell Cancer Treated With Interleukin-12 , 2001, Journal of immunotherapy.

[18]  M. Wiznerowicz,et al.  Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice , 2000, Cancer Gene Therapy.

[19]  T. Nukiwa,et al.  Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma , 2000, Cancer Gene Therapy.

[20]  P. Musiani,et al.  The Combined Action of IL-15 and IL-12 Gene Transfer Can Induce Tumor Cell Rejection Without T and NK Cell Involvement1 , 2000, The Journal of Immunology.

[21]  V. Cerundolo,et al.  Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. , 2000, Cancer research.

[22]  Lieping Chen,et al.  Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. , 2000, Journal of the National Cancer Institute.

[23]  N. Yang,et al.  Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism , 2000, Cancer Gene Therapy.

[24]  Y. Nimura,et al.  Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model , 2000, Cancer Immunology, Immunotherapy.

[25]  J. Prieto,et al.  Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.

[26]  P. Morrissey,et al.  Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice , 2000, The Journal of experimental medicine.

[27]  J. D. Young,et al.  The emerging role of IL-15 in NK-cell development. , 2000, Immunology today.

[28]  J. Leonard,et al.  Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. , 1999, Blood.

[29]  J. Gołąb,et al.  Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. , 1999, European cytokine network.

[30]  J. Gołąb,et al.  Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). , 1999, International journal of molecular medicine.

[31]  N. Yang,et al.  Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. , 1999, Journal of immunotherapy.

[32]  W. Muller,et al.  Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors , 1998, Gene Therapy.

[33]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[34]  D. Schadendorf,et al.  Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study , 1998, Gene Therapy.

[35]  P. Lollini,et al.  Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. , 1998, Cancer research.

[36]  M. Kurimoto,et al.  Antitumor Effects on Mouse Melanoma Elicited by Local Secretion of Interleukin-12 and Their Enhancement by Treatment with Interleukin-18 , 1998, Cancer investigation.

[37]  T. Mak,et al.  Role for IL-15/IL-15 receptor beta-chain in natural killer 1.1+ T cell receptor-alpha beta+ cell development. , 1997, Journal of immunology.

[38]  A. Sher,et al.  In Vivo Microbial Stimulation Induces Rapid CD40 Ligand–independent Production of Interleukin 12 by Dendritic Cells and their Redistribution to T Cell Areas , 1997, The Journal of experimental medicine.

[39]  A. Dabrowska,et al.  Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice , 1997, Cancer Immunology, Immunotherapy.

[40]  N. Yang,et al.  Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. , 1997, Human gene therapy.

[41]  S. Jenks.  After initial setback, IL-12 regaining popularity. , 1996, Journal of the National Cancer Institute.

[42]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[43]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[44]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[45]  T. Strom,et al.  IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.

[46]  J. Lodolce,et al.  The Pleiotropic Functions of Interleukin 15: Not So Interleukin 2–like After All , 2000 .

[47]  A. Burny,et al.  Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. , 1999, International journal of cancer.

[48]  G. Trinchieri.  Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.